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Background: CA125 is the most promising ovarian cancer screening biomarker to date. Multiple 146 
studies reported CA125 levels vary by personal characteristics, which could inform personalized 147 
CA125 thresholds. However, this has not been well described in premenopausal women.  148 
Methods: We evaluated predictors of CA125 levels among 815 premenopausal women from the 149 
New England Case Control Study (NEC). We developed linear and dichotomous (≥ 35 U/ mL) 150 
CA125 prediction models and externally validated an abridged model restricting to available 151 
predictors among 473 premenopausal women in the European Prospective Investigation into 152 
Cancer and Nutrition Study (EPIC). 153 
Results: The final linear CA125 prediction model included age, race, tubal ligation, endometriosis, 154 
menstrual phase at blood draw, and fibroids, which explained 7% of the total variance of CA125. 155 
The correlation between observed and predicted CA125 levels based on the abridged model 156 
(including age, race, and menstrual phase at blood draw) had similar correlation coefficients in 157 
NEC(r=0.22) and in EPIC(r=0.22). The dichotomous CA125 prediction model included age, tubal 158 
ligation, endometriosis, prior personal cancer diagnosis, family history of ovarian cancer, number 159 
of miscarriages, menstrual phase at blood draw and smoking status with AUC of 0.83. The 160 
abridged dichotomous model (including age, number of miscarriages, menstrual phase at blood 161 
draw, and smoking status) showed similar AUCs in NEC(0.73) and in EPIC(0.78). 162 
Conclusions: We identified a combination of factors associated with CA125 levels in 163 
premenopausal women. 164 
Impact:  Our model could be valuable in identifying healthy women likely to have elevated CA125 165 







Introduction  171 
Ovarian cancer is the eighth leading cause of cancer death in 2012 with 151,900 deaths worldwide 172 
due, in part, to lack of specific symptoms leading to diagnosis at late stage when prognosis is 173 
poor(1,2).  More than 80% of ovarian cancer patients have elevated cancer antigen 125 (CA125), 174 
a membrane bound glycosylated mucin (MUC16), which is used clinically as a prognostic 175 
biomarker and to monitor response to therapy(3,4). However, results from two large randomized 176 
screening trials in primarily postmenopausal women using transvaginal ultrasound and CA125 177 
(either using 35 U/ml as a cutoff, or the risk of ovarian cancer algorithm (ROCA)) showed no 178 
clinically significant benefit(5,6).  MUC16 is expressed on a variety of tissues, including the lung, 179 
pancreas, stomach, liver, endometrium, and breast, and levels vary between individuals based on 180 
demographic, reproductive and lifestyle characteristics(7-11). Therefore, identifying personal 181 
characteristics that are associated with CA125 levels could be used to create personalized 182 
thresholds for CA125 instead of a single 35 U/mL cutoff, thereby improving the interpretation of 183 
measured CA125 and its performance as a screening biomarker and ultimately leading to decreased 184 
ovarian cancer mortality.  185 
However, prior studies examining factors associated with CA125 have focused on postmenopausal 186 
women(7,8). Thus, we evaluated factors associated with CA125 in premenopausal women and 187 
developed and validated CA125 prediction models (linear and dichotomous) among 188 
premenopausal women without ovarian cancer from the New England Case-Control Study and the 189 
European Prospective Investigation into Nutrition and Cancer study.  190 
 191 
Materials and Methods 192 
Study population  193 
The New England Case Control Study (NEC) is a population-based case-control study of ovarian 194 
cancer with 2,100 population-based controls enrolled from New Hampshire and eastern 195 
Massachusetts over the three study phases (1992-97, 1998-2002, 2003-2008). Details on the study 196 
design have been described previously(12-14). Briefly, controls were identified using random-197 
digit dialing, town book selection, and drivers’ license lists and frequency matched on age and 198 
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state of residence. Approximately half (54%) of the eligible controls that were contacted agreed to 199 
participate.  We restricted the study population to controls (n=2,100) and excluded women without 200 
CA125 measurements (n=96), women postmenopausal at time of blood draw (n=1,130), women 201 
who had hysterectomy due to unknown menopausal status (n=30), women who were pregnant or 202 
breastfeeding at time of blood draw (n=25), and women with extreme CA125 values ranging from 203 
115.3U/ mL to 411.7 U/mL (n=4) identified based on the generalized extreme studentized deviated 204 
many-outlier detection approach applied to log-transformed values(15). In sum, our analysis 205 
included 815 premenopausal NEC controls. 206 
The European Prospective Investigation into Cancer and Nutrition (EPIC) study is a multicenter 207 
prospective cohort including participants from ten Western European countries developed to 208 
evaluate the association between nutrition and cancer. Briefly, 519,978 participants (366,521 209 
women) were enrolled between 1991 and 1998 across 23 research centers. Details on the study 210 
design have been described previously(16). A nested case-control study of ovarian cancer was 211 
designed within the cohort(17). For each ovarian cancer case, up to four controls were randomly 212 
selected using incidence density sampling for a total of 1,939 controls(17). We excluded women 213 
without CA125 measurements (n=12), women who were either postmenopausal (n=1,416), or had 214 
a hysterectomy or unknown menopausal status (n=38). There were no outlying values in these 215 
EPIC controls. In sum, our analysis included a total of 473 premenopausal EPIC controls. 216 
 217 
CA125 measurements 218 
In NEC controls we measured CA125 using the CA125II radioimmmunoassay (Centocor, 219 
Malvern, PA) at the CER Lab at Boston Children’s Hospitals. We assessed the reproducibility of 220 
the assay by including five blinded aliquots of a uniform quality control pool in each of the 46 221 
assay batches. The average of the coefficients of variation (CV) was 1%. In EPIC controls and in 222 
a subset of NEC controls, we previously measured CA125 using the volume-effective highly 223 
sensitive multiplex platform (Meso Scale Discovery (MSD), Gaithersburg, MD) in the Genital 224 
Tract Biology Laboratory at Brigham and Women’s Hospital(17). The average CV across the 225 




Candidate predictors 228 
We selected factors that have been previously reported to be associated with CA125 in at least one 229 
prior study(7-9,11), ovarian cancer risk factors(18), as well as several factors which were 230 
biologically plausible to be associated with CA125(10). Those included age at blood draw, race, 231 
body mass index (BMI, kg/m2), smoking status (never, former, current), pack-years calculated by 232 
number of packs of cigarettes per day multiplied by the number of years a person had smoked, age 233 
at menarche, oral contraceptive use and its duration (months), parity, self-reported endometriosis, 234 
tubal ligation, family history of ovarian cancer, prior personal cancer diagnosis, caffeine intake 235 
(mg), genital powder use, infertility, number of miscarriages, ectopic pregnancy, ever use of 236 
intrauterine device (IUD), fibroids, menstrual cycle regularity and days between last menstrual 237 
period (LMP) and blood draw(7-11). Furthermore, we evaluated additional variables related to 238 
menstrual characteristics and pregnancy timing: cycle length, days with menstrual bleeding, 239 
dysmenorrhea, age at first live birth, age at last live birth, and years since last live birth. 240 
 241 
Statistical analyses 242 
We log-transformed CA125 values to achieve a normal distribution. With this transformation, the 243 
distribution of log-transformed CA125 was normally distributed with skewness of 0.35 and 244 
kurtosis of 0.34, with a bell-shaped histogram. . 245 
 246 
Recalibration of CA125 247 
Since the EPIC samples had CA125 measured using an alternate assay (MSD assay) with a 248 
different scale, we used recalibration to rescale these measurement results to be comparable to the 249 
CA125II assay values. We recalibrated the EPIC CA125 values based on 187 NEC premenopausal 250 
controls with CA125 measurements on both CA125II and MSD assays using the drift correction 251 
method(19). We regressed the log-transformed MSD assay values to the log-transformed CA125II 252 
assay values and used the intercept and effect estimates of the model to calculate the recalibrated 253 
CA125II assay values based on the measured MSD assay values for all premenopausal controls in 254 
EPIC and used the recalibrated values in our analyses.  255 
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Predictors of CA125 in premenopausal women 256 
First, we evaluated the association between individual candidate predictors and CA125 using linear 257 
or logistic regression adjusted for continuous age. We used effect estimates of the linear regression 258 
for each predictor to calculate the percent change in CA125 levels, calculated as [exp (beta) - 1] 259 
x100 for a 1-unit change in the predictor. We determined the optimal modeling of continuous 260 
variables (age, BMI, age at menarche, duration of OC use, parity, and smoking pack-years) using 261 
restricted cubic splines to test for linearity(20). We used categorical variables for age, dichotomous 262 
variable for age at menarche, and piecewise linear spline with single knot for BMI since these 263 
variables were non-linearly associated with log-transformed CA125. We created composite 264 
categorical variables for OC use and duration and smoking status and pack-years, and compared 265 
nested models using likelihood ratio test and non-nested models using the Akaike information 266 
criterion and Vuong test(21). Based on these evaluations, candidate predictors were modeled as 267 
follows: age at blood draw (categorical, by 10 year intervals from age 30), race (white, non-white), 268 
BMI (piecewise linear spline model with single knot at 27), height (continuous, centered at 165), 269 
smoking status(categorical, never, former, current) and pack-years (continuous, never smokers, 270 
pack-years among former smokers, pack-years among current smokers), age at menarche (age 12 271 
and under, above 12), duration of OC use (continuous, including never users), parity (continuous), 272 
endometriosis (no, yes), tubal ligation (no, yes), family history of ovarian cancer (no, yes), prior 273 
personal cancer diagnosis (no, yes), caffeine intake (quartiles), genital powder use (no use, body 274 
use, genital use), infertility (no, yes), number of miscarriages (0, 1, 2, 3 or more), ectopic 275 
pregnancy (no, yes), intrauterine device use (never, ever), fibroids (no, yes), menstrual cycle 276 
regularity (regular, irregular) and predicted phase of the menstrual cycle (early follicular, late 277 
follicular, peri-ovulatory, luteal, long cycle, irregular, missing) based on the number of days 278 
between the last menstrual period and blood draw. 279 
 280 
Prediction modeling 281 
Overall, we developed CA125 prediction models (linear and dichotomous) in NEC and conducted 282 
external validation in EPIC (Figure 1).  We used cross-validation to conduct internal validation of 283 
the model developed in NEC. Since information on some of the predictors were not collected in 284 
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EPIC, we developed an abridged model restricted to variables available in EPIC from the final 285 
model, and then validated the abridged model in EPIC. 286 
 287 
Linear model 288 
First, we developed a linear CA125 prediction model of log-transformed CA125 in NEC.  We used 289 
stepwise linear regression analysis using p<0.15 as significance level for entry and retention in the 290 
model. In our primary prediction modeling, we used missing indicators for menstrual phase at 291 
blood draw due to a proportion of missing values. For variables with a limited number of missing 292 
values (age at menarche (n=1), caffeine intake (n=23), menstrual cycle length (n=23)), women 293 
with missing values were excluded.  Age was forced in the model and the r-squared was calculated 294 
for the final prediction model, adjusted for study phase (1992-1997, 1998-2003, 2003-2008) and 295 
center (Massachusetts, New Hampshire). In addition, we calculated a delta r-squared that excluded 296 
the variability explained by study phase and center as these were matching factors in NEC and 297 
were forced into the model(22). The predicted log-transformed CA125 values in NEC were 298 
calculated using the effect estimates from the final prediction model. We evaluated the 299 
performance of the model by calculating the Pearson correlation coefficient to assess how well the 300 
predicted and the observed CA125 values agreed (i.e. calibration). We used 5-fold cross-validation 301 
to assess for overfitting in NEC and calculated the average r-squared across all sampled 302 
datasets(23). To evaluate potential bias due to missing data of candidate predictors, we conducted 303 
a sensitivity analysis restricted to women who had no missing predictors. We also conducted 304 
multiple imputation by chained equations (MICE) to impute the missing variables conditional on 305 
all of the predictors and outcome(24). We allowed 100 iterations and generated 20 imputed 306 
datasets. We applied the final prediction model in the 20 imputed datasets using the methods 307 
described and pooled the results of the model estimates using the Rubin’s rules(25).  308 
 309 
For external validation, we sought to validate our linear CA125 prediction model in EPIC. 310 
However, some of our key predictors (endometriosis and fibroids) were not collected in EPIC or 311 
were missing in majority of women (tubal ligation), thus, we validated an abridged model 312 
restricted to variables available in EPIC. First, among the predictors selected in the final model 313 
developed in NEC, we identified predictors available both in NEC and EPIC. We next ran the 314 
abridged model in NEC restricting to those variables available in both NEC and EPIC. We used 315 
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the effect estimates from this model to calculate the predicted value of log-transformed CA125 in 316 
the EPIC samples. We calculated the Pearson correlation coefficient between the predicted and the 317 
observed log-transformed CA125 to assess agreement and compare to that in the discovery dataset. 318 
We plotted the predicted versus the observed log-transformed CA125 for visual assessment. 319 
  320 
Dichotomous model 321 
Next, we developed and validated a dichotomous prediction model of elevated CA125 defined as 322 
having CA125 ≥ 35 U/ mL following the same method used for developing the linear CA125 323 
prediction model described above but using logistic stepwise regression analysis. We evaluated 324 
the performance of the model by calculating the area under the curve (AUC) in the NEC 325 
(discovery) and EPIC (validation). 326 
 327 
All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC), 328 
STATA version 12.1 (StataCorp, College Station, TX), and R version 3.4.3. 329 
 330 
Results 331 
Overall, the mean CA125 values were 17.3 U/ mL in 815 NEC controls and 14.9 U/ mL in 473 332 
EPIC controls after recalibration. The baseline characteristics of NEC and EPIC premenopausal 333 
women were similar except age at blood draw, race, age at menarche, OC use, current hormone 334 
use, infertility, parity, and tubal ligation were significantly different. (Supplementary Table S1). 335 
 336 
Recalibration of CA125 337 
We recalibrated the CA125 values in EPIC using the recalibration model based on 187 NEC 338 
premenopausal controls with both CA125II and MSD assay measurements. These two 339 
measurements were highly correlated (r=0.96, 95%CI 0.94, 0.97). After recalibration, the 340 
measured and recalibrated CA125 values also showed high correlation (r=0.95, 95%CI 0.93, 0.96). 341 




Predictors of CA125 in premenopausal women 344 
Age at blood draw was non-linearly associated with CA125, with women younger than 30 or more 345 
than 50 years old having significantly lower CA125 than those aged 30-39 years (Table 1). In age-346 
adjusted models, menstrual phase at blood draw was significantly associated with CA125 levels, 347 
with early follicular phase levels being 8 to 21% higher than in other menstrual phases. 348 
Endometriosis and fibroids were associated with significantly higher CA125 levels, with 21 and 349 
13% difference, respectively, compared to those who did not have the condition. Current hormonal 350 
contraception use and tubal ligation were significantly associated with lower CA125 levels, with 351 
-16% and -11% difference, respectively. Cycle length, days with menstrual bleeding, 352 
dysmenorrhea, age at first live birth, age at last live birth, and years since last live birth were not 353 
significantly associated with CA125 levels in premenopausal women. Similar predictors were 354 
significantly associated with CA125 levels in the dichotomous model (Supplementary Table S2).  355 
 356 
Linear CA125 prediction modeling 357 
The final linear CA125 prediction model included age at blood draw, race, tubal ligation, 358 
endometriosis, menstrual phase at blood draw, and fibroids, with an r-squared of 0.07 (95%CI 359 
0.02, 0.09) (Table 2). The association between individual predictors and CA125 were similar in 360 
univariate and multivariate adjusted models. The r-squared of this full linear model when 361 
conducting 5-fold cross-validation was 0.02. When we restricted the analysis to the 498 controls 362 
with complete information on all predictors and applied the final linear CA125 prediction model, 363 
the r-squared was 0.12 (95%CI 0.05, 0.15) (Supplementary Table S3). When restricting to women 364 
with complete information on all predictors, the same variables were retained in the final model. 365 
For all the models, the delta r-squared, which subtracts the variance attributable to study phase and 366 
center from the total variance, was similar to the r-squared reported above. When evaluating the 367 
final continuous model in multiple imputed datasets in NEC, the beta coefficients, standard errors, 368 
and the r-squared were similar to the original model (Supplementary Table S3). The small 369 
differences in the measures of association when running the final model in the dataset using 370 
missing indicators, dataset restricted to those with complete information on all potential predictors, 371 
and multiple imputed datasets suggest that the missingness of menstrual phase at blood draw do 372 
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not largely influence the results. We also observed similar performance of the model when 373 
including all significant predictors in the univariate analyses, suggesting that the final model 374 
included important key predictors. Predicted log-transformed CA125 calculated based on the final 375 
model and the observed log-transformed CA125 were weakly correlated with a Pearson correlation 376 
coefficient of 0.26 (95%CI 0.19, 0.33) (Figure 2A). 377 
 378 
For external validation, we developed an abridged linear CA125 prediction model which included 379 
age at blood draw, race, and menstrual phase at blood draw with r-squared of 0.05 (95%CI 0.01, 380 
0.07) in NEC (Table 2). Using the measures of association from this abridged model, we calculated 381 
the predicted log-transformed CA125 values in EPIC. The predicted log-transformed CA125 382 
values had a similar correlation with the observed log-transformed CA125 values in EPIC (r=0.22 383 
(95%CI 0.13, 0.31)) as in the NEC abridged linear model (r=0.22 (95%CI 0.15, 0.29)) (Figure 2B, 384 
2C). The spread of the predicted CA125 values in Figure 2 are much smaller than the spread of 385 
the observed CA125 values because the linear prediction model only explains a small proportion 386 
of the total variance of the observed CA125 values. 387 
 388 
Dichotomous CA125 prediction modeling 389 
The final dichotomous prediction model to predict women with CA125 ≥ 35 U/ mL included age 390 
at blood draw, tubal ligation, endometriosis, prior personal cancer diagnosis, family history of 391 
ovarian cancer, number of miscarriages, menstrual phase at blood draw, and smoking status and 392 
duration with an AUC of 0.83 (95%CI 0.77, 0.89) (Table 3, Figure 3). For menstrual phase at 393 
blood draw, we collapsed the other phase and irregular menstruation categories because few 394 
individuals had CA125 ≥ 35 U/mL in these groups. The association between individual predictors 395 
and CA125 were similar in univariate and multivariate adjusted models. The AUC of this full 396 
dichotomous model when conducting 5-fold cross-validation was 0.67. When we restricted the 397 
analysis to the 498 controls with complete information on all predictors and applied the final 398 
dichotomous model, the AUC was 0.84 (95%CI 0.76, 0.93) (Supplementary Table S4). When we 399 
conducted variable selection process using stepwise regression among women with complete 400 
information on all predictors, similar predictors were retained except number of miscarriages and 401 
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smoking status, resulting with an AUC of 0.79 (95%CI 0.69, 0.89). When evaluating the model in 402 
the multiple imputed datasets in NEC, the odds ratios and the AUC were largely similar to the 403 
primary analysis (Supplementary Table S4). We also observed a similar performance of the model 404 
when including all significant predictors from the univariate analyses, suggesting that the final 405 
model included important key predictors. We also considered using 65 U/mL cutoff which has 406 
been proposed for premenopausal women(26), but were limited with five controls who had CA125 407 
greater than 65 U/mL so were not able to investigate further.  408 
 409 
For external validation, we developed an abridged model, which included age at blood draw, 410 
number of miscarriages, menstrual phase (collapsing those on hormones, blood draw at other 411 
phase, and having irregular menstruation due to power), and smoking status with an AUC of 0.73 412 
(95%CI 0.65, 0.81) in NEC (Table 3, Figure3). When we applied this model to EPIC using 413 
recalibrated CA125 value of 35 U/ mL as cutoff, the AUC was 0.78 (95%CI 0.67, 0.89) (Figure 414 
3).  415 
 416 
Discussion 417 
This is the largest population-based study to develop and validate CA125 prediction models among 418 
healthy premenopausal women considering both continuous levels as well as those over current 419 
clinical threshold of 35 U/ mL. Although, the model predicting continuous CA125 only explained 420 
a small percent of the total variability, the model did show comparable correlations between 421 
predicted and observed levels in EPIC, suggesting the validity of the model. Conversely, the AUC 422 
for predicting elevated CA125 (≥ 35 U/ mL) was relatively high in NEC and validated in EPIC.  423 
 424 
Age was non-linearly associated with CA125 in our study, which is consistent with our prior study 425 
in EPIC in which we observed an inverse U-shaped association between age and CA125 levels 426 
among premenopausal women(9). Similarly, non-white race was associated with significantly 427 
lower CA125, which was consistent with prior studies in postmenopausal women(7,8), suggesting 428 
the need for different thresholds for minority populations. Unfortunately, we were underpowered 429 
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to evaluate differences in prediction models between racial subgroups, though others have 430 
described differences in CA125 levels between Black and Asian women(7,8).  431 
 432 
Factors related to menstruation were strongly related to CA125. Specifically, an early follicular 433 
phase blood draw was significantly associated with higher CA125 levels and strong predictor of 434 
CA125 in our final model, which was consistent with previous reports(27). This association is 435 
likely driven by MUC16 expression on the endometrium and endometrial shedding during early 436 
follicular phase which may lead to higher circulating CA125 levels(10). This could explain the 437 
increased CA125 levels in women with fibroids, since fibroids are known to increase menstrual 438 
bleeding(28). In contrast, MUC16  expression on the endometrium may explain lower CA125 439 
levels among women with a tubal ligation as this procedure would prevent retrograde menstruation, 440 
which occurs in approximately 85% of women during menstruation(29), leading to systemic 441 
exposure to the antigen. Factors related to infertility, particularly endometriosis, were also related 442 
to substantially higher CA125 levels, consistent with prior studies(30,31). A similar mechanism is 443 
likely responsible as endometriosis leads to ectopic endometrial tissue usually in the peritoneal 444 
cavity.  445 
 446 
Our linear CA125 prediction model explained 7% of the variability in CA125 but showed 447 
moderate validation in EPIC, whereas our dichotomous CA125 prediction model had better 448 
predictive ability with good validation. These results suggest that the variability of CA125 may be 449 
small in general but change dramatically by certain factors such as menstrual phase and 450 
endometriosis, and therefore the dichotomous prediction model performed better. We decided to 451 
use a standard log-linear model for developing the linear CA125 prediction model because the 452 
distribution of log-transformed CA125 was normally distributed with low kurtosis and skewness. 453 
When we included all significant predictors in the univariate analyses, both linear and dichotomous 454 
models showed similar performance compared to our final model having fewer predictors, 455 




Interestingly, some factors, such as fibroids and race were only significantly associated with 458 
continuous CA125 and some factors, such as prior personal cancer diagnosis and family history of 459 
ovarian cancer were only significantly associated with elevated CA125 (above 35 U/ mL). We 460 
suspect more predictors were selected in the final dichotomous CA125 prediction model because 461 
the association between exposures and CA125 were non-linear. 462 
 463 
The major strength of our study is that we had two large independent population-based studies 464 
with detailed information on candidate predictors of CA125 to develop and validate CA125 465 
prediction models among premenopausal women. However, there are several limitations to our 466 
study. First, we had missing data on several variables. While we used missing indicators for our 467 
main analysis, our sensitivity analyses restricting to those with complete information on all 468 
predictors and using multiple imputation showed similar results, suggesting that the method for 469 
handling missing data did not influence overall results. In addition, we evaluated the performance 470 
of our prediction models using cross-validation and conducting external validation in an 471 
independent dataset, in which all the results were similar, suggesting a parsimonious model. 472 
Secondly, we were not able to validate the full prediction models in the independent dataset. 473 
Although we were only able to validate an abridged model in EPIC lacking tubal ligation and 474 
endometriosis, we expect the model performance to be better and closer to what we would have 475 
observed in NEC if we had information on all predictors. Thirdly, our model could be missing 476 
unknown predictors of CA125 since we restricted the candidate predictors to those previously 477 
described, which were mostly conducted among postmenopausal women. The relatively low r-478 
squared of the final linear CA125 prediction model suggest that other candidate predictors may 479 
exist, such as genetic factors, common medications, and dietary factors, opening new opportunities 480 
for future studies. While hysterectomy has been previously described as a predictor of CA125, 481 
only few participants in NEC had hysterectomy. Given their ambiguous menopausal status we 482 
excluded them from current analysis of premenopausal women. Lastly, the model performance in 483 
EPIC could be underestimated because NEC and EPIC used different assays to measure CA125. 484 
However, the CA125 values of the two assays were highly correlated (r=0.96) and the predicted 485 
CA125 values calculated using the recalibration model were also very highly correlated with the 486 




In summary, we developed and validated CA125 prediction models among premenopausal women 489 
in two independent studies that further our understanding of factors that influence CA125 levels 490 
and can therefore be used to optimize ovarian cancer screening with CA125. While performance 491 
of population-level screening for ovarian cancer in premenopausal women may be limited due to 492 
the lower incidence of ovarian cancer in this age range, approximately 30% of ovarian cancers are 493 
diagnosed before age 55.  Furthermore, the impact of ovarian cancer in younger women results in 494 
potentially greater social, emotional, and economic impact. Further studies are needed to identify 495 
new predictors of CA125 to improve the model and to understand the predictors of changes in 496 
CA125 over time based on personal characteristics. 497 
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Table 1. Association between predictors and CA125 levels in premenopausal women without ovarian 
cancer in the New England Case Control Study (n=815) 




Age, years     
       < 30 69 (8) 13 (11,14) -20% 0.001 
       30- 39 215 (26) 16 (15, 17) ref  
       40- 49 374 (46) 15 (15, 16) -5% 0.20 
       50+ 157 (19) 15 (13, 16) -10% 0.05 
       P-trend    0.65 
Race     
       white 778 (95) 15 (15, 16) ref  
       non-white 37 (5) 14 (12, 16) -10% 0.20 
BMI, kg/m2     
       < 20 76 (9) 15 (14, 17) 1% 0.90 
       20- < 25 414 (51) 15 (14, 16) ref  
       25- < 30 206 (25) 15 (14, 16) -1% 0.77 
       30- < 35 84 (10) 16 (14, 17) 3% 0.6 
       35+ 35 (4) 17 (14, 20) 13% 0.16 
       P-trend    0.30 
Height, cm     
       < 160 182 (22) 16 (14, 17) ref  
       160- < 165 218 (27) 14 (13, 15) -8% 0.08 
       165- < 170 231 (28) 16 (15, 17) 1% 0.85 
       170- < 175 128 (16) 15 (14, 17) -1% 0.84 
       175+ 56 (7) 14 (12, 16) -8% 0.25 
       P-trend    0.88 
Smoking     
       never 421 (52) 15 (14, 16) ref  
       former 269 (33) 16 (15, 17) 5% 0.19 
       current 125 (15) 14 (13, 15) -7% 0.16 
Smoking status and duration     
      never smokers 421 (52) 15 (14, 16) ref  
      < 5 packyears among former 140 (17) 16 (15, 17) 5% 0.30 
      5- < 15 packyears among former 79 (10) 16 (15, 18) 8% 0.20 
      15+ packyears among former 50 (6) 15 (13, 17) 1% 0.92 
      < 5 packyears among current 23 (3) 15 (12, 19) 1% 0.93 
      5- < 15 packyears among current 46 (6) 14 (12, 16) -6% 0.47 
      15+ packyears among current 56 (7) 13 (12, 15) -11% 0.11 
Age at menarche, years     
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       ≤ 12  386 (47) 16 (15, 16) ref  
       13+ 428 (53) 15 (14, 15) -6% 0.09 
Oral contraceptive use     
     Never 180 (22) 15 (14, 16) ref  
     Ever 635 (78) 15 (15, 16) 5% 0.25 
Duration of oral contraceptive use  
among ever users, years 
    
      < 2 140 (22) 17 (16, 19) ref  
     2 - 3 133 (21) 15 (14, 17) -10% 0.07 
     4 - 5 103 (16) 15 (14, 17) -11% 0.06 
     6 - 9 125 (20) 15 (13, 16) -14% 0.01 
     10+ 134 (21) 14 (13, 16) -16% 0.005 
     P-trend    0.01 
Current hormonal contraception usec     
     no 427 (82) 15 (15, 16) ref  
     yes 94 (18) 13 (12, 14) -16% 0.003 
Menstrual phase at time of blood 
draw (days) 
    
     early follicular (0 - 7) 126 (15) 17 (15, 18) ref  
     late follicular (8 - 11) 56 (7) 16 (14, 18) -8% 0.31 
     peri-ovulatory (12 - 16) 73 (9) 15 (13, 16) -13% 0.06 
     luteal (17 - 35) 155 (19) 14 (13, 16) -14% 0.01 
     long cycle (36+) 63 (8) 13 (12, 15) -21% 0.002 
     irregular 65 (8) 13 (12, 15) -21% 0.002 
     missing 277 (34) 16 (15, 17) -8% 0.15 
Cause of infertility     
     none 649 (80) 15 (15, 16) ref  
     male factor 20 (2) 17 (14, 21) 12% 0.32 
     tubal 13 (2) 15 (11, 20) -1% 0.92 
     endometriosis 13 (2) 23 (17, 30) 50% 0.004 
     ovulatory 14 (2) 14 (11, 18) -7% 0.59 
     unknown 106 (13)  14 (13, 15) -9% 0.08 
Number of miscarriages     
     0 625 (77) 15 (15, 16) ref  
     1 137 (17) 15 (13, 16) -5% 0.29 
     2+ 53 (7) 14 (13, 17) -6% 0.41 
Ectopic pregnancy     
     no 795 (98) 15 (15, 16) ref  
     yes 20 (2) 16 (13, 20) 5% 0.67 
Parity     
     0 214 (26) 15 (14, 16) ref  
     1 140 (17) 15 (14, 16) 1% 0.82 
     2 264 (32) 15 (14, 16) 3% 0.53 
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     3+ 197 (24) 15 (14, 16) 2% 0.66 
Tubal ligation     
     no 674 (83) 15 (15, 16) ref  
     yes 141 (17) 14 (13, 15) -11% 0.01 
Intrauterine device use     
     never 689 (85) 15 (14, 16) ref  
     ever 126 (15) 16 (15, 17) 6% 0.26 
Unilateral oophorectomy     
     no 808 (99) 15 (15, 16) ref  
     yes 7 (1) 19 (13, 27) 23% 0.28 
Endometriosis     
     no 764 (94) 15 (14, 15) ref  
     yes 51 (6) 18 (16, 21) 21% 0.01 
Fibroids     
     no 737 (90) 15 (14,16) ref  
     yes 78 (10) 17 (15,19) 13% 0.04 
Prior personal cancer diagnosis     
     no 778(95) 15 (15, 16) ref  
     yes 37(4) 17 (15, 20) 15% 0.10 
Family history of ovarian cancer     
     no 795 (98) 15 (15, 16) ref  
     yes 20 (2) 17 (13, 21) 10% 0.40 
Genital powder use     
     no use 484 (59) 15 (15, 16) ref  
     body use 157 (19) 15 (14, 16) -5% 0.30 
     genital use 174 (21) 15 (14, 16) -3% 0.57 
Caffeine intake, mg     
     < 70.1 198 (25) 16 (14, 17) ref  
     70.1- < 169.6 198 (25) 14 (13, 15) -9% 0.07 
     169.6- < 348.7 198 (25) 15 (14, 17) 0% 0.97 
     348.7+ 198 (25) 16 (15, 17) 1% 0.90 
     P-trend       0.44 
ageometric mean adjusted for age     
bage-adjusted     
c includes oral contraceptives and 
injections 







Table 2. Linear CA125 prediction model in premenopausal women using stepwise regression in the 
New England Case Control Study (NEC) 
Selected Predictors 
Development of model in NEC 
(n=768)a b 
  









Age, years        
     < 30 -18% 0.07 0.01  -19% 0.07 0.004 
     30- < 40 ref    ref 
  
     40- < 50 -8% 0.04 0.06  -8% 0.04 0.05 
     50+ -10% 0.06 0.06  -11% 0.06 0.04 
Non-white race -13% 0.09 0.10  -14% 0.09 0.08 
Tubal ligation -10% 0.05 0.03        
Endometriosis 21% 0.07 0.01        
Menstrual phase at time of blood 
draw     
   
     early follicular phase ref    ref 
  
     on hormonal contraceptivesc -28% 0.07 <.0001  -27% 0.07 <.0001 
     other cycle phase -17% 0.06 0.002  -17% 0.06 0.001 
     irregular cycles -30% 0.11 0.001  -30% 0.11 0.001 
     missing -17% 0.10 0.05  -18% 0.10 0.04 
Fibroids 13% 0.06 0.04         
R-squared 0.07   0.05 
aadjusted for study phase and center     
bexclude missing age at menarche(n=1), caffeine intake(n=23), and menstrual cycle length(n=23)  
c includes oral contraceptives and injections   











Table 3. Dichotomous CA125 prediction model of high CA125 ( ≥ 35 U/ mL) in 
premenopausal women using stepwise regression in the New England Case Control Study 
(NEC) 
Selected predictors 
Development of model 
in NEC(n=768) a b 
  
Abridged model in 
NEC(n=768)a b  
  Odds ratio 95%CI   Odds ratio 95%CI 
Age, years      
     < 30 0.34 0.07, 1.61  0.29 0.06, 1.30 
     30- < 40 ref  
 ref  
     40- < 50 0.34 0.15, 0.74  0.40 0.20, 0.82 
     50+ 0.37 0.13, 1.04  0.44 0.17, 1.12 
Tubal ligation 0.16 0.03, 0.73      
Endometriosis 3.08 1.09, 8.72      
Prior personal cancer diagnosis 5.41 1.70, 17.18      
Family history of ovarian cancer 13.32 3.42, 51.93      
Number of miscarriages      
     0 ref   ref  
     1 0.23 0.06, 0.89  0.36 0.11, 1.21 
     2+ 0.18 0.02, 1.56  0.29 0.04, 2.18 
Menstrual phase at time of blood draw      
     regular menstruation  
     + blood draw at early follicular phase 
ref   ref  
     on hormonal contraceptives c 0.07 0.01, 0.63  
0.35 0.15, 0.82       regular menstruation  
     + blood draw at other phase 
     /irregular menstruation 
0.49 0.19, 1.25  
     missing time at blood draw  0.62 0.08, 4.70  0.35 0.05, 2.45 
Smoking status      
     Never ref   ref  
     Former 2.15 0.97, 4.79  1.85 0.96, 3.57 
     Current 0.12 0.01, 1.51  0.47 0.13, 1.64 
     Pack-years among former smokers 0.99 0.94, 1.05      
     Pack-years among current smokers 1.09 1.00, 1.18      
AUC  (95%CI) 0.83 0.77, 0.89   0.73 0.65, 0.81 
aadjusted for study phase and center      
bexclude missing age at menarche(n=1), caffeine intake(n=23), and menstrual cycle length(n=23) 




Figure Legend 614 
Figure 1. Study design of the development and validation of the CA125 prediction model 615 
using the New England Case Control Study (NEC) and European Prospective Investigation 616 
into Cancer and Nutrition Study (EPIC) 617 
We developed the CA125 prediction models (linear and dichotomous) using the New England 618 
Case Control Study (NEC) and conducted external validation using the European Prospective 619 
Investigation into Cancer and Nutrition Study (EPIC). 620 
 621 
Figure 2. Development and validation of linear CA125 prediction model in the New England 622 
Case Control Study (NEC) and European Prospective Investigation into Cancer and 623 
Nutrition Study (EPIC) 624 
The predicted versus the observed log-transformed CA125 values were plotted and Pearson 625 
correlation coefficient (r) was calculated to assess the performance of the linear CA125 prediction 626 
model in the New England Case Control Study (NEC) and European Prospective Investigation 627 
into Cancer and Nutrition Study (EPIC).  A, Linear CA125 prediction model performance in NEC. 628 
B, Abridged linear CA125 prediction model performance in NEC. C, Abridged linear CA125 629 
prediction model performance in EPIC. 630 
 631 
Figure 3. Development and validation of dichotomous CA125 prediction model the New 632 
England Case Control Study (NEC) and European Prospective Investigation into Cancer 633 
and Nutrition Study (EPIC) 634 
Receiver Operating Characteristic (ROC) curves were plotted and the Area Under the Curve 635 
(AUC) was calculated to assess the discriminatory performance of the dichotomous CA125 636 
prediction model in the New England Case Control Study (NEC) and European Prospective 637 
Investigation into Cancer and Nutrition Study (EPIC).  Dichotomous CA125 prediction model 638 
performance in NEC (solid line), abridged dichotomous CA125 prediction model performance in 639 
27 
 
NEC (dashed line), abridged dichotomous CA125 prediction model performance in EPIC (dotted 640 
line). 641 
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